Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Oxaliplatin 296Fluorouracil 272Bevacizumab 236Gemcitabine 235Leucovorin 212Capecitabine 204pembrolizumab 202Nivolumab 156Irinotecan 156Cisplatin 150Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73lenvatinib 68Folfox protocol 68Carboplatin 66Blood Specimen Collection 61regorafenib 60trifluridine tipiracil drug combination 53Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
crenigacestat × Gastrointestinal × 1 year × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡